Results 71 to 80 of about 3,108,169 (356)

Epigenetic Regulation in Melanoma: Facts and Hopes

Cells, 2021
Cutaneous melanoma is a lethal disease, even when diagnosed in advanced stages. Although recent progress in biology and treatment has dramatically improved survival rates, new therapeutic approaches are still needed.
Emilio Francesco Giunta, Gianluca Arrichiello, Marcello Curvietto, Annalisa Pappalardo, Davide Bosso, Mario Rosanova, Anna Diana, Pasqualina Giordano, Angelica Petrillo, Piera Federico, Teresa Fabozzi, Sara Parola, Vittorio Riccio, Brigitta Mucci, Vito Vanella, Lucia Festino, Bruno Daniele, Paolo Antonio Ascierto, Margaret Ottaviano, On Behalf of SCITO YOUTH   +19 more
doaj   +1 more source

Nivolumab plus ipilimumab in the treatment of advanced melanoma. [PDF]

, 2015
Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that
Daud, Adil I, Tsai, Katy K
core   +1 more source

Acidic microenvironment plays a key role in human melanoma progression through a sustained exosome mediated transfer of clinically relevant metastatic molecules [PDF]

, 2018
Background: Microenvironment cues involved in melanoma progression are largely unknown. Melanoma is highly influenced in its aggressive phenotype by the changes it determinates in its microenvironment, such as pH decrease, in turn influencing cancer cell
A Albini, A Lardner, Alessandra Carè, AR Hess, Bok Hong, C Coscia, Carla Raggi, CC Jiang, CP Lai, Cristiana Zanetti, D Hanahan, E Alegre, E Willms, EK Rofstad, Elin J Ekström, Elisabetta Pizzi, Fabrizio Mattei, Federica Felicetti, Federica Fratini, G Helmlinger, G Raposo, H Mizuno, H Peinado, I Lazar, I Parolini, IF Robey, Isabella Parolini, J Kowal, J Lotvall, J Niu, J Skog, J Webber, Jessica Lamberti, JL Hood, JL Hood, JL Wike-Hooley, JM Graham, JR Knutson, K Al-Nedawi, Katia Fecchi, Luca Fantozzi, Luca Pasquini, M Colombo, M Logozzi, Massimo Sanchez, Massimo Sargiacomo, MR Muhsin-Sharafaldine, N Raghunand, O WARBURG, P Vaupel, R Valenti, RE Moellering, Rossella Puglisi, S Dror, S Dutta, S Peppicelli, SK Huang, Stefania D’Atri, T Fiaschi, T Fukamachi, T Groot Kormelink, T Kobayashi, V Estrella, V Pospichalova, V Vukovic, XY Yam, Y Ishihama, Zaira Boussadia   +67 more
core   +10 more sources

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

Cell, 2020
Neoantigens arise from mutations in cancer cells and are important targets of T cell-mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-
P. Ott, S. Hu-Lieskovan, B. Chmielowski, R. Govindan, A. Naing, N. Bhardwaj, K. Margolin, M. Awad, M. Hellmann, Jessica J. Lin, T. Friedlander, M. Bushway, Kristen N. Balogh, Tracey E. Sciuto, Victoria L. Kohler, S. Turnbull, Rana H. Besada, Riley R. Curran, Benjamin Trapp, J. Scherer, A. Poran, D. Harjanto, D. Barthelme, Ying S. Ting, Jesse Z. Dong, Yvonne Ware, Yuting Huang, Zhengping Huang, Amy Wanamaker, Lisa D. Cleary, M. A. Moles, K. Manson, J. Greshock, Z. Khondker, E. Fritsch, Michael S. Rooney, M. DeMario, R. Gaynor, L. Srinivasan   +38 more
semanticscholar   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

Molecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets   +12 more
wiley   +1 more source

Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma [PDF]

, 2015
Background: Immune markers in the peripheral blood of melanoma patients could provide prognostic information. However, there is currently no consensus on which circulating cell types have more clinical impact.
Bachert, Claus, Brochez, Lieve, CHEVOLET, INES, Krysko, Olga, Neyns, Bart, Schreuer, Max, Speeckaert, Reinhart, van Geel, Nanja, Van Gele, Mireille   +8 more
core   +2 more sources

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma

Cancer immunology research, 2021
This exploratory analysis investigating biomarkers of response to nivolumab and ipilimumab in melanoma patients demonstrates that combined assessment of tumor mutational burden, an inflammatory gene signature, and BRAF mutation status has the potential ...
F. Hodi, J. Wolchok, D. Schadendorf, J. Larkin, G. Long, Xiaozhong Qian, A. Saci, Tina C. Young, S. Srinivasan, Han Chang, Hao Tang, M. Wind-Rotolo, J. Rizzo, D. Jackson, P. Ascierto   +14 more
semanticscholar   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

The treatment of Advanced Melanoma: Current approaches and new challenges.

Critical reviews in oncology/hematology
In recent years, advances in melanoma treatment have renewed patient hope. This comprehensive review emphasizes the evolving treatment landscape, particularly highlighting first-line strategies and the interplay between immune-checkpoint inhibitors (ICIs)
A. Boutros, E. Croce, M. Ferrari, R. Gili, Giulia Massaro, R. Marconcini, L. Arecco, E. Tanda, F. Spagnolo   +8 more
semanticscholar   +1 more source

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma

Cancers, 2021
Simple Summary Talimogene laherparepvec (T-VEC; IMLYGIC®, Amgen Inc.) is the first oncolytic viral immunotherapy to be approved for the local treatment of unresectable metastatic stage IIIB/C–IVM1a melanoma.
P. Ferrucci, L. Pala, F. Conforti, E. Cocorocchio   +3 more
semanticscholar   +1 more source